Preston D. Steen

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire

Debra L. Barton, Rui Qin, Preston D. Steen et al. · Quality of Life Research · 2013 · 188 citations

Patient-reported Peripheral Neuropathy, Health Sciences, Peripheral Nerve Injury +10

A phase III study of radiation therapy plus carmustine with or without recombinant interferon-? in the treatment of patients with newly diagnosed high-grade glioma

Jan C. Buckner, Paula J. Schomberg, William L. McGinnis et al. · Cancer · 2001 · 138 citations · Full text

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

Joel W. Neal, Suzanne E. Dahlberg, Heather A. Wakelee et al. · The Lancet Oncology · 2016 · 133 citations · Full text

Medicine, Cancer Management, Metronomic Therapy +10

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study

Steven R. Alberts, Nathan R. Foster, Roscoe F. Morton et al. · Annals of Oncology · 2005 · 105 citations · Full text

Pancreatic Cancer, Gastrointestinal Oncology, Metastatic Pancreatic Adenocarcinoma +9